Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
October 30 2023 - 8:00AM
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology
company focused on developing and launching the first curative
targeted cell therapies for patients with autoimmune diseases,
today announced that the Company will participate in three upcoming
investor conferences in November:
- Guggenheim 5th Annual Inflammation, Neurology, &
Immunology Conference: Steven Nichtberger, M.D., Chief
Executive Officer, will participate in a fireside chat on Monday,
November 6, 2023 at 9:50 a.m. ET in New York, NY. Members of
management will also be available for one-on-one meetings.
- Stifel 2023 Healthcare Conference: Gwendolyn
Binder, Ph.D., President of Science and Technology, will
participate in a fireside chat on Tuesday, November 14, 2023 at
4:45 p.m. ET in New York, NY. Members of management will also be
available for one-on-one meetings.
- 6th Annual Evercore ISI HealthCONx Conference:
Steven Nichtberger, M.D., Chief Executive Officer, will participate
in a fireside chat on Wednesday, November 29, 2023 at 8:20 a.m. ET
in Miami, FL. Members of management will also be available for
one-on-one meetings.
A live webcast of the presentations will be available on the
News and Events section of the Company’s website at
www.cabalettabio.com. Replays will be available on the website for
30 days.
About Cabaletta BioCabaletta Bio (Nasdaq: CABA)
is a clinical-stage biotechnology company focused on the discovery
and development of engineered T cell therapies that have the
potential to provide a deep and durable, perhaps curative,
treatment for patients with autoimmune diseases. The CABA™ platform
encompasses two strategies: the CARTA (chimeric antigen receptor T
cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing
fully human CD19-CAR T, as the lead product candidate being
evaluated in systemic lupus erythematosus, myositis, and systemic
sclerosis, and the CAART (chimeric autoantibody receptor T cells)
strategy, with multiple clinical-stage candidates, including
DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK
myasthenia gravis. The expanding CABA™ platform is designed to
develop potentially curative therapies that offer deep and durable
responses for patients with a broad range of autoimmune diseases.
Cabaletta Bio’s headquarters and labs are located in Philadelphia,
PA.
Contacts:
Anup MardaChief Financial Officerinvestors@cabalettabio.com
William GramigStern Investor Relations,
Inc.william.gramig@sternir.com
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Apr 2024 to May 2024
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From May 2023 to May 2024